Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions.
In HIV-1-infected patients with long-term undetectable viraemia on highly active antiretroviral treatment (HAART), we found that pre-HAART plasma viraemia and the baseline proviral DNA level were significantly associated with the viraemia setpoint during scheduled treatment interruptions. In long-term treated patients, pre-HAART viraemia may not be available, and in these circumstances proviral DNA, measured at the time of scheduled treatment interruption, can help to identify patients likely to reach a low viraemia setpoint after treatment interruption.
Yerly
Sabine
S
Günthard
Huldrych F
HF
Fagard
Catherine
C
Joos
Béda
B
Perneger
Thomas V
TV
Hirschel
Bernard
B
Perrin
Luc
L
D023241:Antiretroviral Therapy, Highly Active; D015331:Cohort Studies; D004279:DNA, Viral; D015658:HIV Infections / Q000188:drug therapy / Q000235:genetics* / Q000821:virology; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D015999:Multivariate Analysis; D009154:Mutation / Q000235:genetics; D012367:RNA, Viral / Q000235:genetics; D014766:Viremia / Q000235:genetics / Q000821:virology
D004279:DNA, Viral; D012367:RNA, Viral